Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 2591)

VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW VETINARY DRUG APPLICATION ACCEPTED FOR EFSUBAGLUTIDE ALFA

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the "**Company**" together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders of the Company (the "**Shareholders**") and potential investors of its recent business updates.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 4 February 2026, an Investigational New Veterinary Drug application for the Company's Core Product (i.e. Efsubaglutide Alfa) for the treatment of companion animal diabetes has been officially accepted by the Ministry of Agriculture and Rural Affairs of the People's Republic of China (中華人民共和國農業農村部) (the "**MARA**"). It is expected that Phase I clinical trials will be commenced in the first quarter of 2026.

The Board believes that research and development of diabetic medicine for companion animals has great prospects. As individuals are more willing to accept and spend money on prolonging the lives of domestic pets, the Board is of the view that such research and development aligns with the Group's long term business development strategy, which will lay a solid foundation for the Group's expansion into companion animal drug products in the long run.

The Group has complied with all relevant standards and regulatory requirements for veterinary drug research and registration stipulated by the MARA, and has successfully completed the relevant pre-clinical trials. Based on pre-clinical trial results, it was noted that Efsubaglutide Alfa yielded positive results in companion animal diabetes management in terms of efficacy and safety, and would provide reasonable basis for subsequent clinical trials and registration applications related to such drug.

The Company will continue to update the Shareholders and potential investors on material progress in accordance with applicable regulatory requirements.

Cautionary Statement: The Company cannot guarantee that it will be able to ultimately develop and/or market Efsubaglutide Alfa for the treatment of companion animal diabetes successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People's Republic of China, 4 February 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.